FDA expands approval of brentuximab vedotin to PTCLNovember 16, 2018T Cell LymphomasAggressive Lymphomas
NHL patients report fear, isolation during chemoNovember 15, 2018Aggressive LymphomasPatient & Survivor Care
Relapsed MCL: Options for treatmentNovember 15, 2018Mantle Cell LymphomaAggressive LymphomasB Cell Lymphoma
Novel risk factors for febrile neutropenia in NHL, solid tumorsNovember 2, 2018Patient & Survivor CareAggressive Lymphomas
Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphomaOctober 31, 2018Aggressive LymphomasB Cell Lymphoma
Line complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphomaOctober 25, 2018Aggressive LymphomasThrombosisB Cell Lymphoma
First-line bortezomib prolongs survival in MCLOctober 25, 2018Mantle Cell LymphomaAggressive LymphomasB Cell Lymphoma
Older age predicts mortality after alloHCT in NHL, but not relapseOctober 24, 2018Aggressive LymphomasCellular TherapyB Cell Lymphoma
Study challenges LVEF assessment before DLBCL treatmentOctober 19, 2018Aggressive LymphomasB Cell Lymphoma
Entospletinib falls short in relapsed/refractory DLBCLOctober 11, 2018Aggressive LymphomasB Cell Lymphoma
Updated ThroLy system predicts need for thromboprophylaxisOctober 11, 2018ThrombosisAggressive LymphomasIndolent Lymphoma
MCL treatment choices depend partly on ageOctober 10, 2018Mantle Cell LymphomaAggressive LymphomasB Cell Lymphoma
